In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional neuroendocrine tumors of GI or lung origin are rare forms of cancer with poor prognoses and … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged advanced nonfunctional gastrointestinal, Afinitor®, lung NET, Novartis
Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at a major medical meeting; worldwide regulatory filings are planned for 2015 Afinitor is already … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged advanced gastrointestinal, Afinitor®, lung neuroendocrine tumors, Novartis
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
